Today, shortly after the opening bell, VolitionRx announced that it has engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.
“VolitionRx is developing a blood-based cancer diagnostics tool that in preclinical trials has demonstrated tremendous potential to change the landscape of colorectal cancer screening,” stated Sherri Franklin, Director of Marketing at MissionIR. “As the Company continues its focus on ongoing clinical trials of this product, MissionIR will work to increase VolitionRx’s visibility among the investment community and strengthen dialogue with existing Company shareholders. We’re excited to be a part of VolitionRx’s future.”
Cameron Reynolds, CEO of VolitionRx, stated, “This new partnership with MissionIR will enhance our current investor relations initiatives and help us to execute a strategic campaign to better reach and communicate with our shareholders. Additionally, as we continue with the advancement of our cancer diagnostic tests, we look forward to working with MissionIR’s team to maximize product exposure and attain our short-term and long-term goals. MissionIR is providing a much needed service not only to VolitionRx, but to the broader small-cap market.”
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream — an indication that cancer is present. VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests.
For more information on VolitionRx, visit http://VNRX.MissionIR.com